Zealand’s obesity drug shouldn’t disrupt Novo Nordisk-Eli Lilly leadership: Mizuho’s Jared Holz

Jared Holz, Mizuho Americas, joins ‘Fast Money’ to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.